These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 23582093)

  • 21. PI3K inhibitors in cardiovascular disease.
    Eisenreich A; Rauch U
    Cardiovasc Ther; 2011 Feb; 29(1):29-36. PubMed ID: 20626398
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway.
    Nahta R; O'Regan RM
    Clin Breast Cancer; 2010 Nov; 10 Suppl 3():S72-8. PubMed ID: 21115425
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of the phosphatidylinositol 3-kinase (PI3K) pathway in the development and treatment of uterine cancer.
    Naumann RW
    Gynecol Oncol; 2011 Nov; 123(2):411-20. PubMed ID: 21903247
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nuclear phospho-Akt increase predicts synergy of PI3K inhibition and doxorubicin in breast and ovarian cancer.
    Wallin JJ; Guan J; Prior WW; Edgar KA; Kassees R; Sampath D; Belvin M; Friedman LS
    Sci Transl Med; 2010 Sep; 2(48):48ra66. PubMed ID: 20826841
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treating breast cancer through novel inhibitors of the phosphatidylinositol 3'-kinase pathway.
    Crowder RJ; Ellis MJ
    Breast Cancer Res; 2005; 7(5):212-4. PubMed ID: 16168140
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Isoform-Selective PI3K Inhibitors for Various Diseases.
    Bheemanaboina RRY
    Curr Top Med Chem; 2020; 20(12):1074-1092. PubMed ID: 31903879
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting the phosphoinositide-3 (PI3) kinase pathway in breast cancer.
    Baselga J
    Oncologist; 2011; 16 Suppl 1():12-9. PubMed ID: 21278436
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [PI3K-AKT-mTOR pathway inhibitors].
    Cortot A; Armand JP; Soria JC
    Bull Cancer; 2006 Jan; 93(1):19-26. PubMed ID: 16455502
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway inhibition: a breakthrough in the management of luminal (ER+/HER2-) breast cancers?
    Zardavas D; Fumagalli D; Loi S
    Curr Opin Oncol; 2012 Nov; 24(6):623-34. PubMed ID: 22960556
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Challenges of developing therapeutics that target signal transduction in patients with gynecologic and other malignancies.
    Rowinsky EK
    J Clin Oncol; 2003 May; 21(10 Suppl):175s-186s. PubMed ID: 12743132
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drugging PI3K in cancer: refining targets and therapeutic strategies.
    Yap TA; Bjerke L; Clarke PA; Workman P
    Curr Opin Pharmacol; 2015 Aug; 23():98-107. PubMed ID: 26117819
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phosphatidylinositol-3-kinase as a putative target for anticancer action of clotrimazole.
    Furtado CM; Marcondes MC; Carvalho RS; Sola-Penna M; Zancan P
    Int J Biochem Cell Biol; 2015 May; 62():132-41. PubMed ID: 25794423
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The PI3K pathway as drug target in human cancer.
    Courtney KD; Corcoran RB; Engelman JA
    J Clin Oncol; 2010 Feb; 28(6):1075-83. PubMed ID: 20085938
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibitors of phosphatidylinositol-3-kinase in cancer therapy.
    Ihle NT; Powis G
    Mol Aspects Med; 2010 Apr; 31(2):135-44. PubMed ID: 20176047
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Current and Investigational Agents Targeting the Phosphoinositide 3-Kinase Pathway.
    Tang LA; Dixon BN; Maples KT; Poppiti KM; Peterson TJ
    Pharmacotherapy; 2018 Oct; 38(10):1058-1067. PubMed ID: 30120858
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapeutic potential of phosphoinositide 3-kinase inhibitors.
    Ward S; Sotsios Y; Dowden J; Bruce I; Finan P
    Chem Biol; 2003 Mar; 10(3):207-13. PubMed ID: 12670534
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cardiovascular toxicity of PI3Kα inhibitors.
    Sadasivan C; Zhabyeyev P; Labib D; White JA; Paterson DI; Oudit GY
    Clin Sci (Lond); 2020 Oct; 134(19):2595-2622. PubMed ID: 33063821
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Progress in the preclinical discovery and clinical development of class I and dual class I/IV phosphoinositide 3-kinase (PI3K) inhibitors.
    Shuttleworth SJ; Silva FA; Cecil AR; Tomassi CD; Hill TJ; Raynaud FI; Clarke PA; Workman P
    Curr Med Chem; 2011; 18(18):2686-714. PubMed ID: 21649578
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Management of Cancer Patients with Cardiovascular Complications - Onco-Cardiology].
    Mukai M
    Gan To Kagaku Ryoho; 2016 Aug; 43(8):940-4. PubMed ID: 27539035
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cancer Kinases and its Novel Inhibitors: Past, Present and Future Challenges.
    Pillai P; Surenya RS; Nair SV; Lakshmanan VK
    Curr Drug Targets; 2015; 16(11):1233-45. PubMed ID: 25882221
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.